Searchable abstracts of presentations at key conferences in endocrinology

ea0090oc4.5 | Oral Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Reprogramming of reproductive signals via human luteinizing hormone/choriogonadotropin receptor (LHCGR)/G protein-coupled estrogen receptor (GPER) heteromers

Lazzaretti Clara , Paradiso Elia , Sperduti Samantha , Sayers Niamh , Pelagatti Ginevra , D'Alessandro Sara , Perri Carmela , Baschieri Lara , Mascolo Elisa , Roy Neena , Simoni Manuela , Hanyaloglu Aylin , Casarini Livio

In the ovary, the G protein-coupled estrogen receptor (GPER) forms heteromeric complexes with the follicle-stimulating hormone receptor (FSHR), reprogramming FSH-induced signals and determining the follicular fate. Based on the structural similarity, we evaluated whether GPER interacts with the luteinizing hormone (LH)/choriogonadotropin (hCG) receptor (LHCGR) modulating gonadotropin-dependent signals. LHCGR-GPER heteromers were evaluated in transiently transfected HEK293 cell...

ea0090rc2.5 | Rapid Communications 2: Thyroid | ECE2023

Lack of GPER-TSHR heteromers is a hallmark of thyroid cancer

Perri Carmela , D'Alessandro Sara , Paradiso Elia , Lazzaretti Clara , Mascolo Elisa , Baschieri Lara , Roy Neena , Sperduti Samantha , Simoni Manuela , Brigante Giulia , Casarini Livio

Thyroid cancer is the most common type of endocrine tumor and reaches the peak of incidence between the age of twenty and fifty years. It has 4-fold higher prevalence in females than males, suggesting that estrogens and their receptors could be involved in thyroid cancer pathogenesis. Previous studies demonstrated allosteric interference operated by G protein-coupled estrogen receptor (GPER) to molecules structurally similar to the thyroid-stimulating hormone (TSH) receptor (T...

ea0090p443 | Reproductive and Developmental Endocrinology | ECE2023

Protein kinase B (Akt) blockade inhibits LH/hCG-mediated 17,20-lyase, but not 17α-hydroxylase activity of CYP17a1 in mouse Leydig cell steroidogenesis

Paradiso Elia , Lazzaretti Clara , Sperduti Samantha , Melli Beatrice , Perri Carmela , D'Alessandro Sara , Baschieri Lara , Mascolo Elisa , Roy Neena , Simoni Manuela , Casarini Livio

Androgens are sex steroid hormones fundamental for human reproduction. In males, they are produced upon luteinizing hormone (LH) action through its specific receptor (LHCGR) expressed in Leydig cells, supporting spermatogenesis. The human chorionic gonadotropin (hCG), acting on the same receptor but not expressed in men, is administered to improve testosterone synthesis in specific pathological contexts, such as hypogonadotropic hypogonadism and cryptorchidism. In vitro</e...

ea0063gp58 | Acromegaly and GH | ECE2019

ACROSTUDY – safety and efficacy in a cohort of 110 Naïve patients with acromegaly treated with pegvisomant

Wajnrajch Michael , Gomez Roy , Hey-Hadavi Judith , Kelepouris Nikoletta , van der Lans Joli , Loftus Jane , Camacho-Hubner Cecilia , Fleseriu Maria , Salvatori Roberto , Cara Jose , Palladino Andrew

Background: ACROSTUDY is an open-label, non-interventional post-authorization safety study that began in 2004 to evaluate safety in at least 1000 acromegaly patients treated with the GH receptor antagonist pegvisomant (PEGV). This commitment was fulfilled in Jan 2013. ACROSTUDY was later amended to enroll an additional 110 patients that were naïve/semi-naive to PEGV treatment. Semi-naïve patients are defined as not having received PEGV therapy for at least 6 months p...

ea0063p955 | Diabetes, Obesity and Metabolism 3 | ECE2019

Transgenic production of endogenous n-3 PUFA levels compared to fish oil intake differentially improve obesity-related metabolic disorders: role of the gut microbiota

Barz Melanie Le , Daniel Noemie , Varin Thibault V , Mitchell Patricia , Pilon Genevieve , Gauthier Josee , Garofalo Carole , Kang Jing X , Roy Denis , Jobin Christian , Levy Emile , Marette Andre

Previous studies demonstrated that n-3 polyunsaturated fatty acids (PUFA) reduce insulin resistance and non-alcoholic fatty liver disease (NAFLD). However, we previously reported that transgenic expression of the fat-1 n-3 desaturase, inducing the endogenous production of n-3 PUFA, improved insulin resistance but not hepatic steatosis in a mouse model of obesity. Thus, we compared the effects of increasing n-3 PUFA levels through oral or endogenous approaches in diet-...

ea0043oc19 | Design a Clinical Program for Success | WCTD2016

Development of an electronic clinical decision support system: “mWellcare – an Integrated mHealth System for Prevention and Care of Chronic Diseases”

Jindal Devraj , Jha Dilip , Gupta Priti , Vamadevan Ajay S. , Roy Ambuj , Venugopal Vidya , Prieto-Merino David , Perel Pablo , Tandon Nikhil , Patel Vikram , Prabhakaran Dorairaj

Background: Diabetes and hypertension are among leading causes of premature adult deaths in India. Innovative approaches such as electronic clinical decision support systems (DSS) could play major role in improving quality and access to diabetes and hypertension care at primary care settings.Objective: The main objective of this study is to develop an innovative tablet-computer based DSS namely “m-WELLCARE”, and other essential support healthca...

ea0041gp235 | Thyroid Cancer (1) | ECE2016

Thyroid nodules: a highly specific molecular and cytological combined predictor of malignancy

Lasolle Helene , Riche Benjamin , Decaussin Myriam , Dantony Emmanuelle , Cornu Catherine , Lifante Jean-Christophe , Capraru Oana-Maria , Rousset Bernard , Borson-Chazot Francoise , Roy Pascal

Thyroid nodules are very common and benign in most cases. Thus, malignancy detection avoiding overtreatment is a challenge. Nodule evaluation mainly supports on US and fine needle aspiration cytology (FNAC). The Bethesda classification (BC) for reporting thyroid cytopathology is now currently used for the interpretation of results but it does not enable classifying 30% of samples.The objective was to identify, by transcriptome analysis, a molecular signa...

ea0038p398 | Steroids | SFEBES2015

Discrimination of adrenocortical carcinoma from other adrenal lesions: use of a new 13 steroid serum panel based on LC–MS/MS

Taylor David , Ghataore Lea , Vincent Royce , Sherwood Roy , Whitelaw Ben , Dworakowska Dorota , Schulte Klaus-Martin , Diaz-Cano Salvadore , Lewis Dylan , Aylwin Simon , Taylor Norman

Adrenocortical carcinoma (ACC) is a rare malignancy, but accounts for up to 11% of adrenal masses investigated in referral centres. Diagnosis remains a challenge. Up to two thirds are biochemically inactive, resulting from de facto enzyme deficiencies in the steroid hormone biosynthetic pathways, as shown by urine steroid profiling by gas chromatography-mass spectrometry. Increased metabolites of pathway intermediates in ACC discriminate it from benign adrenal lesions...

ea0037ep1350 | Endocrine nursing | ECE2015

Continuous subcutaneous hydocortisone infusion replacement treatement in adrenal insufficiency – how to start the hydrocortisone infusion

Simunkova Katerina , Jovanovic Nevena , Rostrup Espen , Methlie Paal , Oksnes Marianne , Nilsen Roy Miodini , Henno Hanne , Tilseth Mira , Godang Kristin , Kovac Ana , Lovas Kristian , Husebye Eystein Sverre

Many patients with primary adrenal insufficiency (Addison’s disease) take extra doses of glucocorticoids before or during stressful events, but benefit has not been demonstrated. We aimed to test the effect of an extra dose of glucocorticoids on cardiorespiratory, hormonal and metabolic parameters in response to physical activity in a randomised placebo-controlled, 2-weeks cross-over, clinical trial (clinicaltrials.gov NTC01847690). Ten women with Addison’s disease a...

ea0035p33 | Adrenal cortex | ECE2014

Circadian cortisol and GH profiles in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy

Oksnes Marianne , Bjornsdottir Sigridur , Isaksson Magnus , Methlie Paal , Nilsen Roy , Kampe Olle , Hulting Anna-Lena , Husebye Eystein , Lovas Kristian , Nystrom Thomas , Bensing Sophie

Background: Conventional glucocorticoid replacement therapy in patients with Addison’s disease (AD) is unphysiological with possible adverse effects on mortality, morbidity and quality of life. Physiological amounts of glucocorticoids are required for normal GH production and release and a chronically raised cortisol level, suppresses the secretion of GH with possible metabolic and cardiovascular consequences. The diurnal cortisol profile can likely be restored by continu...